For more than 8 million people in the U.S. living with psoriatic disease, biologics promise improved symptom management and slower disease progression. However, for many, gaining access to needed therapies is like being trapped in healthcare’s most frustrating escape room. Barriers to specialty medications begin the moment the doctor starts the prescribing process.
Psoriasis Action Month, which takes place every August, is a reminder that this scenario plays out all too often. Here are some ways that end-to-end engagement technology solves those challenges:
Prior authorization (PA) is often the first barrier patients encounter for specialty medication access. It’s needed in 71% of cases for infused rheumatologic medications, with 21% initially denied, leading to treatment delays of two weeks or longer.
Navigating prescribing requirements for specialty medications is another challenge providers and patients encounter. For example, a physician may select the patient’s preferred retail pharmacy by default, unaware that the prescribed therapy has a limited distribution network and needs to be sent to a specific pharmacy or it can’t be filled.
Financial barriers are some of the most difficult puzzles patients face. Nearly half (46%) of Medicare patients diagnosed with psoriasis abandon biologic therapy within one year, with cost being a significant driver. For some patients, the cost is simply too high to start treatment.
Some barriers are internal. Patients may worry about side effects or be uncomfortable with the idea of injections or infusions. These unspoken concerns often lead them to abandon therapy.
Even after patients start treatment, new obstacles can appear. Formulary changes or reauthorization requirements can get in the way of ongoing adherence. So can forgetfulness. Even unforeseen events can influence adherence. During the COVID-19 pandemic, over 30% of patients with psoriasis faced treatment disruptions due to access challenges.
Specialty medication barriers are more than frustrating—they’re clinically significant. Medication delays and nonadherence can lead to serious complications, including hospital admissions for uncontrolled symptoms.
Adherence and persistence rates for widely used therapies like etanercept, adalimumab, and infliximab typically range between 50% and 60%, indicating a need keep patients engaged and informed to keep therapy on track.
Pharmaceutical companies play a pivotal role in unlocking specialty medication barriers. Using an end-to-end engagement platform, you can deliver messages at critical moments throughout the prescribing and onboarding process, helping patients access therapies that improve health outcomes.
Next step: Want to learn how Timely by DrFirst breaks through specialty medication barriers? Check out this success story for an injectable biologic.